These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19424623)

  • 1. Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin.
    Niyazi M; Marini P; Daniel PT; Humphreys R; Jendrossek V; Belka C
    Oncol Rep; 2009 Jun; 21(6):1455-60. PubMed ID: 19424623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a triple treatment with irradiation, agonistic TRAIL receptor antibodies and EGFR blockade.
    Niyazi M; Marini P; Daniel PT; Humphreys R; Jendrossek V; Belka C
    Strahlenther Onkol; 2009 Jan; 185(1):8-18. PubMed ID: 19224142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.
    Marini P; Denzinger S; Schiller D; Kauder S; Welz S; Humphreys R; Daniel PT; Jendrossek V; Budach W; Belka C
    Oncogene; 2006 Aug; 25(37):5145-54. PubMed ID: 16636678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
    Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A
    Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
    Belyanskaya LL; Marti TM; Hopkins-Donaldson S; Kurtz S; Felley-Bosco E; Stahel RA
    Mol Cancer; 2007 Oct; 6():66. PubMed ID: 17953743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies.
    Gong J; Yang D; Kohanim S; Humphreys R; Broemeling L; Kurzrock R
    Mol Cancer Ther; 2006 Dec; 5(12):2991-3000. PubMed ID: 17148761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
    Wu XX; Kakehi Y
    Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
    Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
    Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors.
    Stadel D; Mohr A; Ref C; MacFarlane M; Zhou S; Humphreys R; Bachem M; Cohen G; Möller P; Zwacka RM; Debatin KM; Fulda S
    Clin Cancer Res; 2010 Dec; 16(23):5734-49. PubMed ID: 20940278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.
    Natoni A; MacFarlane M; Inoue S; Walewska R; Majid A; Knee D; Stover DR; Dyer MJ; Cohen GM
    Br J Haematol; 2007 Nov; 139(4):568-77. PubMed ID: 17922877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
    Younes M; Georgakis GV; Rahmani M; Beer D; Younes A
    Eur J Cancer; 2006 Mar; 42(4):542-7. PubMed ID: 16426839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo.
    Pukac L; Kanakaraj P; Humphreys R; Alderson R; Bloom M; Sung C; Riccobene T; Johnson R; Fiscella M; Mahoney A; Carrell J; Boyd E; Yao XT; Zhang L; Zhong L; von Kerczek A; Shepard L; Vaughan T; Edwards B; Dobson C; Salcedo T; Albert V
    Br J Cancer; 2005 Apr; 92(8):1430-41. PubMed ID: 15846298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway.
    Ohtsuka T; Buchsbaum D; Oliver P; Makhija S; Kimberly R; Zhou T
    Oncogene; 2003 Apr; 22(13):2034-44. PubMed ID: 12673208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo.
    Zeng Y; Wu XX; Fiscella M; Shimada O; Humphreys R; Albert V; Kakehi Y
    Int J Oncol; 2006 Feb; 28(2):421-30. PubMed ID: 16391797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin.
    Chan LP; Chou TH; Ding HY; Chen PR; Chiang FY; Kuo PL; Liang CH
    Biochim Biophys Acta; 2012 Jul; 1820(7):1081-91. PubMed ID: 22554915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis.
    Marini P; Schmid A; Jendrossek V; Faltin H; Daniel PT; Budach W; Belka C
    BMC Cancer; 2005 Jan; 5():5. PubMed ID: 15651986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
    Ravi R; Bedi A
    Cancer Res; 2002 Mar; 62(6):1583-7. PubMed ID: 11912124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
    Smith MR; Jin F; Joshi I
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.
    Strekalova E; Malin D; Good DM; Cryns VL
    Clin Cancer Res; 2015 Jun; 21(12):2780-91. PubMed ID: 25724522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
    Nawrocki ST; Carew JS; Douglas L; Cleveland JL; Humphreys R; Houghton JA
    Cancer Res; 2007 Jul; 67(14):6987-94. PubMed ID: 17638911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.